News | May 02, 2026
Indoco Remedies to exit ophthalmic business in strategic sale to Sunways India
The transaction marks a clear portfolio reshuffle for Indoco
The transaction marks a clear portfolio reshuffle for Indoco
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
His appointment is expected to further strengthen the company’s financial governance and regional operational strategy across South Asia
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
The approval was driven by data from the Phase III TULIP-SC trial
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
